循环林依赖的激酶抑制剂p19Ink4dd的结构
F Y Luh1, S J Archer, P J Domaille
1Cambridge Centre for Molecular Recognition, Department of Biochemistry, University of Cambridge, UK.
Nature
|November 14, 1997
概括
p19Ink4d的结构揭示了Ink4蛋白中的突变如何破坏癌症途径. 这一发现有助于设计针对Rb路径的新型癌症疗法.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 结构生物学 结构生物学
背景情况:
- 癌症经常涉及瘤抑制途径的破坏,特别是涉及p53和Rb的途径.
- 该Rb通路调节细胞循环的进展,并且在癌症中经常通过Rb,cyclin D1,Cdk4和p16Ink4a等关键蛋白的突变而改变.
研究的目的:
- 使用NMR光谱测定p19Ink4d蛋白质的结构.
- 了解p16Ink4a中的突变如何导致功能丧失.
- 为治疗开发提供Ink4-cyclin-Cdk相互作用的模型.
主要方法:
- 核磁共振 (NMR) 光谱法用于确定蛋白质结构.
- 在p16Ink4a.a中分析与癌症相关的突变.
- Ink4蛋白相互作用的结构建模.
主要成果:
- 阐明了p19Ink4d的NMR结构.
- 这项研究表明,p16Ink4a中的功能丧失突变通常是由于蛋白质错误折叠或不可溶性的结果.
- 建议使用Ink4蛋白与环林-Cdk复合物的相互作用模型.
结论:
- 确定p19Ink4d的结构为Ink4家族的环林依赖性激酶抑制剂 (CDKI) 提供了洞察力.
- 了解突变的结构后果对于癌症治疗至关重要.
- 拟议的相互作用模型可以指导设计针对Rb通路的新型癌症治疗方法.
相关概念视频
01:45Positive Regulator Molecules
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
01:23Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...